Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 4/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863850 | 0.92 | MMP1 (0.51) | MMP1MMP9MMP13ADAM17CNR1 | |
| SCHEMBL5864250 | 0.92 | MMP1 (0.51) | MMP1MMP9MMP13ADAM17CNR2 | |
| SCHEMBL5863789 | 0.91 | LTA4H (0.53) | MMP1MMP9MMP13ADAM17LTA4H | |
| SCHEMBL5863929 | 0.89 | PGR (0.54) | MMP1MMP9MMP13ADAM17LTA4H | |
| SCHEMBL5863617 | 0.89 | KCNH2 (0.48) | MMP1MMP9MMP13ADAM17LTA4H | |
| SCHEMBL5863389 | 0.88 | MMP1 (0.57) | MMP1MMP9MMP13ADAM17CNR1 | |
| SCHEMBL5863870 | 0.88 | MMP1 (0.44) | MMP1MMP9MMP13ADAM17LTA4H | |
| SCHEMBL5863424 | 0.88 | MMP1 (0.44) | MMP1MMP9MMP13ADAM17LTA4H | |
| SCHEMBL5863692 | 0.88 | MMP1 (0.51) | MMP1MMP9MMP13ADAM17CNR1 | |
| SCHEMBL5863578 | 0.88 | MMP1 (0.45) | MMP1MMP9MMP13ADAM17LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | MMP1 1746/4885MMP9 2415/4885MMP13 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.